Methodology Change | Solactive United States Biotechnology Index | Effective Date 30/05/2023

Today, on the 23/05/2023, Solactive announces the following changes to the methodology of the following index/Indices (the ‘Affected Indices’):

Rationale for Methodology Change

The Indices aim to represent US listed securities that have business operations in the biotechnology industry. This includes companies that are headquartered in and outside of the United States. Solactive would like to suggest decreasing the exposure to companies that are not headquartered in the United States.

Therefore, Solactive proposes to implement a single security cap of 4% on American depositary receipt.

Changes to the Index Guideline

The following Methodology changes are proposed in the following points of the Index Guideline (ordered in accordance with the numbering of the affected sections):

Section 2.3 Weighting of the Index Components

From (old version):

 “[…]

• The individual maximum weight of the top five Index Components by Free Float Market Capitalization is at 8%.
• All other Index Components are capped at 4%

 […]”

To (new version):

 “[…]

• The individual maximum weight of each American depositary receipt is at 4%.
• The individual maximum weight of the top five Index Components by Free Float Market Capitalization is at 8%.
• All other Index Components are capped at 4%

 […]”